<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <title>INRange - Pragmatic Trials Collaborative</title>
    <meta name="description" content="A western Canadian group of primary care providers collaborating on pragmatic trials to evaluate practice changes on patient-oriented outcomes" />
    <meta name="author" content="Enhancing Alberta Primary Care Networks (EnACt)" />
    <link rel="shortcut icon" type="image/ico" href="/images/icon.ico" />
    <link href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.6/css/bootstrap.min.css" rel="stylesheet" media="screen">
    <link href="https://maxcdn.bootstrapcdn.com/font-awesome/4.6.3/css/font-awesome.min.css" rel="stylesheet" media="screen">
    <!--[if lt IE 9]>
      <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/respond.js/1.4.2/respond.min.js" integrity="sha512-qWVvreMuH9i0DrugcOtifxdtZVBBL0X75r9YweXsdCHtXUidlctw7NXg5KVP3ITPtqZ2S575A0wFkvgS2anqSA==" crossorigin="anonymous" referrerpolicy="no-referrer"></script>
    <![endif]-->
    <link href='https://fonts.googleapis.com/css?family=Roboto:400,700,500,300italic,400italic,500italic,700italic,300,200' rel='stylesheet' type='text/css'>
    <link href='https://fonts.googleapis.com/css?family=Kreon:400,300,700' rel='stylesheet' type='text/css'>
    <link href='/css/pragmatic.css' rel='stylesheet' type='text/css' media="screen,print">
    <link href='/css/pragmatic-print.css' rel='stylesheet' type='text/css' media="print">
  </head>
  <body>
    <div class="container">
      <div class="row header">
        <div class="logo col-sm-4 col-md-3">
          <img src="/images/caduceus.svg" />
        </div>
        <div class="col-sm-8 col-md-9">
          <h1>Pragmatic Trials&nbsp;Collaborative</h1>
          <h2>Measuring&nbsp;What&nbsp;Matters</h2>
        </div>
      </div>
      <div class="row">
        <div class="nav col-md-3 col-sm-4">
          <nav>
            <ul>
              <li class=""><a href="/">About Us</a></li>
              <li class=""><a href="/what/">Why Pragmatic Trials?</a></li>
              <li class="section-label">Trials In Progress</li>
              <li class="section-sub"><a href="/minmed/">MinMed</a></li>
              <li class="section-sub"><a href="/optimizebp/">OptimizeBP</a></li>
              <li class="section-label">Completed Trials</li>
              <li class="section-sub active"><a href="/inrange/">INRange</a></li>
              <li class="section-sub"><a href="/bedtime-diuretics/">Bedtime Diuretics</a></li>
              <li class="section-sub"><a href="/bedmed/">BedMed</a></li>
              <li class="section-sub"><a href="/bedmed-frail/">BedMed-Frail</a></li>              
              <li class="section-label">Working to Improve Trials</li>
              <li class="section-sub"><a href="/avoiding-the-curse/">Avoiding the &quot;Winner's Curse&quot;</a></li>
              <li class=""><a href="/pdsa/">Closing the PDSA Loop</a></li>
              <li class=""><a href="/join/">How To Join</a></li>
            </ul>
          </nav>
        </div>


        <div class="col-md-9 col-sm-8 content">
          <div class="row content-title">
            <h6>Completed Trials</h6>
            <h2>INRange</h2>
            <hr />
            <div>

              <!--
              <p class="big">INRange is our inaugural pragmatic trial. It is primarily intended to pilot our recruitment methods but also allows us to learn whether the safety and effectiveness of the anticoagulant warfarin varies with the time of day it is ingested.</p>

              <div class="media">
                <div class="media-left">
                  <a href="/inrange_poster.pdf">
                    <img class="media-object" src="/images/asa_poster_thumb.png" alt="61st ASA Poster">
                  </a>
                </div>
                <div class="media-body">
                  <p>See <a href="/inrange_poster.pdf">the poster</a> from the 61st <a href="https://www.acfp.ca/what-we-do/annual-scientific-assembly/" target="_blank">Annual Scientific Assembly</a>.</p>
                  <p>The effect of diet and medication timing on anticoagulation stability in the users of warfarin: the "INRange" RCT</p>
                </div>
              </div>
              <h3>Why would we want to look at this?</h3>
              <p>Warfarin is used to reduce the risk of clotting disorders (e.g. stroke) in patients who are predisposed to forming clots. It accomplishes this by interfering with the vitamin K dependent production of clotting factors in the liver<sup><a href="#ref1">1</a></sup>. High oral intake of dietary vitamin K can overcome the effect of warfarin and variability of vitamin K intake is believed to cause fluctuation in warfarin’s effectiveness<sup><a href="#ref2">2</a></sup>. Currently patients are told to take their warfarin at dinnertime – the same time of day in which vitamin K content in meals is most highly variable.  Given vitamin K has an ultra short (2.5 hour) half-life and is cleared from the body quickly<sup><a href="#ref3">3</a></sup>, given warfarin might be more active around the time of day it is ingested (when the liver is exposed to higher warfarin concentrations), and given typical breakfast foods have very little vitamin K, it is possible that taking warfarin at breakfast when the competing vitamin K influence would be more consistent (consistently low) might lead to a more stable anticoagulant effect. This is a highly speculative hypothesis but no studies have ever been conducted evaluating whether the time of day warfarin is ingested matters to its effectiveness. Specifically, this study looks at the proportion of time patients spend outside of the therapeutic INR range (the blood test that assesses warfarin’s effectiveness) and determines whether the proportion of time outside this desired range is lessened when patients take their warfarin in the morning. If so, patients making such a switch may have both less risk of adverse effects (bleeding disorders), and greater effectiveness (less risk of stroke) for no extra cost or inconvenience.</p>
              <p class="registration">Trial registration: <a href="https://clinicaltrials.gov/ct2/show/NCT02376803" target="_blank">NCT02376803</a></p>
              <h3>The Team</h3>
              <div class="team-photo">
                <img src="/images/team_ab_bc.jpg" alt="the team"/>
              </div>
              <h3>Timeline</h3>
              <p>INRange is currently completing follow-up with 236 primary care providers having recruited across British Columbia and Alberta (&frac34; in Alberta). Final results should be available in the spring of 2017.</p>

            </div>
            <div class="references">
              <h5>References</h5>
              <ol>
                <li><a name="ref1"></a>Hirsh J, Fuster V, Ansell J, Halperin JL, American Heart A, American College of Cardiology F. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. <em>Circulation</em>. Apr 1 2003;107(12):1692-1711.</li>
                <li><a name="ref2"></a>Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. <em>The American journal of medicine</em>. May 15 2004;116(10):651-656.</li>
                <li><a name="ref3"></a>Olson RE. The function and metabolism of vitamin K. <em>Annual review of nutrition</em>. 1984;4:281-337.</li>
              </ol>
            </div>
          -->


            <h3>Summary</h3>
            <p>The timing of medications might influence their safety, or their effectiveness. When this project began, warfarin was recommended for evening use, but no studies had evaluated whether warfarin timing actually mattered. INRange organized 236 volunteer family physicians in 54 western Canadian communities to invite their warfarin-using patients (217 of whom participated) to randomly determine the time of day they would use warfarin (morning or evening) for the next 7 months. Warfarin's effectiveness was determined by how often the "INR" blood test (a common test measuring how fast blood clots) was in the desired range. At the end of the study there was no meaningful difference between groups.</p>
            <h3>Bottom Line</h3>
            <p class="big">Warfarin should be taken whenever regular compliance would be easiest.</p>
            <div class="link-list">
              <h3>Study Details &amp; Data Access</h3>
              <ul>
                <li><a href="https://clinicaltrials.gov/ct2/show/NCT02376803">Trial registration</a></li>
                <li><a href="https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1516-9">Published protocol</a></li>
                <li><a href="http://www.annfammed.org/content/18/1/42">Scientific abstract</a></li>
                <li><a href="/inrange/INRangeOpenAnonymizedAnalyticDataset_20200109.xlsx">Analytic data set</a></li>
                <li><a href="https://www.youtube.com/watch?v=9-ectI7Ncx0" target="_blank">Results webinar for trial participants</a></li>
                <li>Citation:
                  <div class="citation" style="padding: 1rem 3rem">
                    <a href="https://www.annfammed.org/content/18/1/42">Garrison SR, Green L, Kolber MR, et al. The effect of warfarin administration time on anticoagulation stability (INRange): a pragmatic randomized controlled trial. <em>Ann Fam Med.</em> 2020;18(1):42-49</a>
                  </div>
                </li>
              </ul>
              <em>Retrieved from: <a href="https://www.annfammed.org/content/18/1/42">https://www.annfammed.org/content/18/1/42</a></em>
            </div>


          </div>



        </div>
      </div>
    </div>
    <br /><br />
  </body>
</html>
